1. Western blotting of PD-L1 mAbs.
Western blotting of PD-L1 mAbs. A, multichannel Western blot analysis with dose curve of each antibody (5, 1.25, 0.31, and μg/mL per lane) on HDLM2, Caki-2, or SKBR3, as indicated. Blot was developed with an equal mixture of anti-mouse and anti-rabbit IgG-HRP antibodies. B, Western blot analysis of hematologic (HDLM2, L428, and OC1-LY1), kidney (Caki-2, UMRC-6, 769C, and SN12C), ovarian (36M2, A2780-C70, and OVCAR3), and breast cancer cell lines (MDA231, SKBR3, and BT474) with anti–PD-L1 mAbs: 5A4 (10 μg/mL), 7G11 (20 μg/mL), 9A11 (5μg/mL), or anti–β-actin A and B are representative of two to five experiments.
Kathleen M. Mahoney et al. Cancer Immunol Res 2015;3:
©2015 by American Association for Cancer Research